RxDoctor Payments Data

Rene Alvarez, MD

Advanced Heart Failure and Transplant Cardiology · Philadelphia, PANPI 1568441129

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $19,030 of the $26,997 with a category attached, or 70.5%. 24 manufacturers reported payments, led by Novartis at 53.0% of the total. Reporting peaked in 2019 at $15,878 and has fallen 95.5% since, to $714 in 2025.

$26,997in general payments, 2019–2025

Across 217 payments — averaging $124.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$14K
  • Akcea Therapeutics, Inc.$6K
  • Abbott$4K
  • AstraZeneca$1K
  • Pfizer$392
  • Cvrx, Inc.$354
  • plus $1K from 18 others

What the payments were for

  • Consulting fees$1,9747%
  • Speaking & faculty fees$19,03070%
  • Travel & lodging$2831%
  • Food & beverage$5,67521%
  • Education$350%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$26,997 in reported general payments places this provider in the 75th percentile of 96 advanced heart failure and transplant cardiology providers in Pennsylvania.

See all advanced heart failure and transplant cardiology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$85,574
Medicare patients
206
Services billed
1,183

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyndamaxTafamidis36$820,994
EntrestoSacubitril/Valsartan247$285,527
VyndaqelTafamidis Meglumine13$272,901
CamzyosMavacamten29$235,183
EliquisApixaban154$139,168
FarxigaDapagliflozin Propanediol45$55,113
JardianceEmpagliflozin11$17,975
XareltoRivaroxaban16$14,236
Repatha SureclickEvolocumab15$11,110
Tacrolimus12$5,512
Metoprolol Succinate154$2,592
Atorvastatin Calcium128$2,451
Carvedilol99$1,569
Rosuvastatin Calcium48$1,514
Warfarin Sodium39$1,223

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerVyndamax, Vyndaqel, Eliquis$392$1,233,062203 claims
NovartisEntresto$14,309$285,527247 claims
E.r. Squibb & Sons, L.L.C.Camzyos$68$235,18329 claims
AstraZenecaFarxiga$1,079$55,11345 claims
Boehringer IngelheimJardiance$15$17,97511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 96 advanced heart failure and transplant cardiology providers in Pennsylvania.

Other advanced heart failure and transplant cardiology in Philadelphia

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →